

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Wah Yan Healthcare Limited

中國華仁醫療有限公司

(Incorporated in the Hong Kong with limited liability)

(Stock Code: 648)

COMPLETION OF ACQUISITION AND APPOINTMENT OF CHIEF EXECUTIVE OFFICER

The Company is pleased to announce that following all of the conditions precedent under the SPA having been fulfilled, completion of the Acquisition took place on 23 June 2016 and the appointments of Dr. Chan as the chief executive officer of the Company and the managing director of the Target Company have also become effective on the same day.

Reference is made to the announcement (the “Announcement”) of the Company dated 7 June 2016 relating to (i) the acquisition of the entire issued share capital of the Target Company principally engaged in the provision of obstetric and gynaecological services in Hong Kong and (ii) the proposed appointment of Dr. Chan as the chief executive officer of the Company. Unless otherwise stated herein, capitalised terms used in this announcement shall have the same meaning as those defined in the Announcement.

COMPLETION OF THE ACQUISITION

The Company is pleased to announce that all of the conditions precedent under the SPA have been fulfilled, and completion of the Acquisition took place on 23 June 2016.

APPOINTMENT OF CHIEF EXECUTIVE OFFICER

Following completion of the SPA, Dr. Chan has been appointed as the chief executive officer of the Company effective from 23 June 2016.

Dr. Chan, age 65, is a specialist in Obstetrics and Gynaecology. He obtained the Bachelor of Medicine and the Bachelor of Surgery from The University of Hong Kong. He also obtained the Australian Medical Council Certification in Australia and the Doctor of Medicine from The National University of Singapore.

Dr. Chan is a Fellow of the Hong Kong Academy of Medicine in both Hong Kong and Singapore, a Fellow of The Hong Kong College of Obstetricians and Gynaecologists, a Fellow of The Royal College of Obstetricians and Gynaecologists, the United Kingdom, a Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, a Fellow of the American College of Surgeons and International College of Surgeons, the United States of America. He is also currently the Honorary Clinical Associate Professor, Department of Obstetrics and Gynaecology of The University of Hong Kong and the Adjunct Associate Professor, School of Biomedical Sciences of The Chinese University of Hong Kong.

Dr. Chan has been a visiting consultant/staff specialist to a number of hospitals in The Philippines, Singapore and Australia. Dr. Chan is presently the Secretary of Asian Federation, the Chairman of Congress and Conference Sub-Committee and the Executive Committee Member of The International College of Surgeons, the United States of America, the Honorary Secretary of the Hong Kong Section of The International College of Surgeons and the Executive Committee Member of the Association of Doctors in Aesthetic Medicine (HK) Ltd.. He was formerly the Chairman and Professor, Discipline of Obstetrics and Gynaecology of The University of Tasmania, Australia and a Staff Specialist, Department of Obstetrics and Gynaecology of Royal Hobart Hospital and Launceston General Hospital, Australia, and the Chairman of the Perinatal Medicine Committee, Tasmania.

Dr. Chan has authored many scholarly papers and book chapters worldwide in obstetrics and gynaecology, infertility, in-vitro fertilization and reproductive technologies. He is also an active participant in the development of in-vitro fertilization and has delivered lectures on invitro fertilization in numerous seminars and symposia including the organization of many invitro fertilization workshops worldwide. Between 1986 and 2000, Dr. Chan and the Reproductive Medicine team of The National University of Singapore had achieved several recognitions being the first in Asia in Assisted Reproductive Technologies and gynaecological endoscopy surgeries including the Science and Technology Award from the Singapore Government in 1989 for the first baby born in the world using the technology of sperm injection into human eggs.

Dr. Chan was educated in Asia, Europe and Australia and had received scholarships from the Government of Hong Kong, The National University of Singapore, The Medical Research Council of Singapore and the French Exchange Award for work and practices in Monash University, Australia, The University of London, Bristol University and Cambridge University, the United Kingdom, and Clermont-Ferrand University, France.

The appointment of Dr. Chan as the chief executive officer of the Company has an initial term of three years and he is entitled to receive an annual salary of HK\$1.56 million plus bonus. Dr. Chan's remuneration is determined by reference to his qualification, experience, duties and responsibilities in the Company.

Save as disclosed above and as far as the Board is aware, Dr. Chan has not held any directorship in other public listed companies in Hong Kong or overseas in the last three years and does not have any relationship with any directors, senior management or substantial shareholders of the Company. As at the date of this announcement, Dr. Chan is not interested in or deemed to be interested in any shares, underlying shares or debentures (as defined under Part XV of the Securities and Future Ordinance, Chapter 571 of the Laws of Hong Kong) of the Company.

Save as disclosed above and as far as the Board is aware, there is no other information which is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules nor are there any other matters that is in relation to the appointment of Dr. Chan that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to warmly welcome Dr. Chan to join the Company.

By Order of the Board of
China Wah Yan Healthcare Limited
Chan Ka Chung
Chairman

Hong Kong, 23 June 2016

As at the date of this announcement, the board of Directors comprises three executive Directors, namely Mr. Chan Ka Chung, Mr. Cheung Wai Kwan and Mr. Wang Jianguo; and four independent non-executive Directors, namely, Mr. Chan Yee Ping, Michael, Ms. Hu Xuezhen, Mr. Lam Chun Ho and Dr. Tong Cheuk Man.